Health Technology Assessment

OHE Lunchtime Seminar with Steve McKenna, 17th September 2019. The seminar will examine conceptual and practical aspects of measuring value in health care.

This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long-run.

OHE Lunchtime Seminar with Anirban Basu, 24th July 2019. The seminar will examine conceptual and theoretic arguments for use of HYT and illustrate their performance.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2019 annual meeting in Cologne, 15-19 June.

A new OHE Research Paper considers whether we can compare and aggregate patient-reported outcome (PRO) data between people and settings. The paper is authored by Nancy Devlin (University of Melbourne), Paula Lorgelly (King’s College London) and Mike Herdman (OHE).

The measurement of quality of life in the context of spinal muscular atrophy (SMA) is challenging. This is because the disease is experienced by children and is rare, which makes data collection difficult. Our...

Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical evidence on the relationship between health outcomes and health expenditures in England. Results suggest that setting a cost-effectiveness criterion for NICE may not be capable of being synthesised using scientific methods alone, but involve political judgements.

The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January 2019. The Japanese proposals do not meet them.

Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the top 10 causes of death in the world. The Center for Global Development and the Office of Health Economics are proposing a new innovation model to bring better TB drugs to market. We call it the “Market-Driven, Value-Based Advance Commitment,” or MVAC for short.

OHE’s Koonal Shah gave a presentation on societal values and the provision of end of life treatments at a Manchester Centre for Health Economics seminar.

Pages

Subscribe to RSS - Health Technology Assessment